Increase in radio targeting per clinic
This book “Development of radio targeting towards clinical precision oncology: Festschrift in honor of Kalevi Kairemo“Includes a unique collection of articles ranging from radionoconfusion and therapy to imaging and therapy that includes sections on thyroid cancer, head and neck cancer, urinary tract cancer, and neuroendocrine tumors. Therapy, nanoparticles and precision oncology have also been addressed in their respective segments. Supporting sciences include metabolic imaging, cardiovascular radionuclide imaging, combination and bone therapy. Finally, Professor Kairemo’s own memoir “Seven Decades in Healthcare” and colleagues ’memoirs, including Kalevi Kairemo’s personal presentation with a photographic program, open up a multidisciplinary human world with a multidisciplinary approach to science, significant development in chemistry and biology. , Engineering, Physics and Clinical Medicine. This book is ideal for imaging and clinical oncology experts to broaden their understanding of the role of radionuclides and should be part of the archives of all individuals, including those in the radionuclide field.
Festschrift in honor of Kalevi Kairemo
Professor Kairemo graduated from the Helsinki University of Technology with a master’s degree in medicine in 1980 before completing a medical degree (MD) (86), Ph.D. (93) at the University of Helsinki. a degree in clinical pharmacology (06) from Helsinki University Central Hospital, and received a doctorate from the Memorial Sloan-Kettering Cancer Center in 1989-93 in New York.
Professor Kairemo has been Professor of Clinical Chemistry at the Norwegian University of Science and Technology (1998-99), Professor of Isotope Medicine at Uppsala University Hospital in Sweden (2001-5) and Head of the Department of Nuclear Medicine, Department of Cancer at Helsinki University Central Hospital (2004-9). From 2009 to 2018, he was Director of Isotope Medicine and Molecular Radiation Therapy at the Docrates Cancer Center in Helsinki. Since 2015, he has been a visiting professor in the Department of Nuclear Medicine at the University of Texas, MD Anderson Cancer Center, Houston, TX; his last visit was in 2019.
Professor Kairemo has also served in the industry as Medical Director of Cancer Targeting Technologies (2001-6), Medical Director of Imanext Ltd (2006-8) and Clinical Director of Advanced Accelerator Applications SA in 2009 (now Novartis Co.). .
Professor Kairemo has extensive experience in the development of antitumor compounds, including monoclonal antibodies, specific phage display peptides and cytotoxic drugs, and has coordinated several EU research-programmed proposals, including a member of the EU National Coordinator and Management Committee. COST Action Project (BM 0607, Targeted Radionuclide Therapy) 2007–2011. He also served as a member of the WARMTH Governing Body from 2009 to 2012 and again in 2018. He has also been active in hosting short-term academic visits for students from developing countries.
In addition to a few patents, Professor Kairemo has published more than 250 original publications in peer-reviewed journals (H-index 34). He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) in 2012, and in November 2012 was appointed President of the 7th International Conference on Radiopharmaceutical Therapy in Levi. In 2014, Dr. Kairemo hosted the ISORBE Symposium and Workshop “Cell Labeling and Cell Therapies” in Helsinki. He also organized the International Symposium on Radiofarmaseutical Therapy (WARMTH) in November 2018 in Helsinki.
Keywords
Radionuclide therapy, radionuclide imaging, cancer imaging, chemotherapy for cancer treatment,
See the link for more information: https://bit.ly/3vTYwhm
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the bulletins sent to EurekAlert! through the participating institutions or through the EurekAlert system.